- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06218030
Adjunctive Treatment With L-methylfolate for Treatment-Resistant Generalized Anxiety Disorder: a Pilot Study
PSIY-744-23: Adjunctive Treatment With L-methylfolate for Treatment-Resistant Generalized Anxiety Disorder: a Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 2V7
- Kingston Health Sciences Centre
-
Principal Investigator:
- Rafael Freire, MD PhD
-
Sub-Investigator:
- Elisa Brietzke, MD PhD
-
Contact:
- Yan Deng
- Phone Number: +1-613-548-7839
- Email: yan.deng@queensu.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults.
- Patients on a stable dose of an selective serotonin uptake inhibitors (SSRI) or serotonin and noradrenaline reuptake inhibitors (SNRI) for at least 8 weeks.
- Treatment-resistant GAD, defined by lack of response to at least two drugs, from two different classes of drugs considered first-line or second-line for GAD according to the Canadian Clinical Practice Guidelines for the Management of Anxiety, Posttraumatic Stress and Obsessive-Compulsive Disorders (Katzman et al., 2014). Only trials lasting at least 8 weeks and with at least the minimum effective dose of the given medication will be considered failed trials.
Exclusion Criteria:
- Patients with moderate to severe major depressive disorder based on the Patient Health Questionnaire - Nine Item (PHQ-9) scale (score of 15 or above) at baseline.
- Mini International Neuropsychiatric Interview version (MINI) 7.0 indicates moderate to high current suicidality or "suicide likely in near future" or current suicidal behavior disorder.
- Patients diagnosed with obsessive-compulsive disorder (OCD), bipolar disorder, schizophrenia, schizoaffective disorder, personality disorders, substance use disorders, intellectual disabilities, dementia, epilepsy or other severe neurological diseases.
- Patients with cardiovascular diseases, infections, inflammatory diseases, recent surgeries, recent physical trauma and other medical issues that could produce elevation of c-reactive protein (CRP) or homocysteine.
- Consumption of cannabis, any cannabis by-products, illicit drugs, or alcohol above 3 drinks per week.
- Supplementation of diet with vitamins or consumption of natural health products that may affect anxiety or depression symptoms.
- Reading competence below Grade 5.
- Participants who do not have capacity to conduct consent process.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: L-methylfolate arm
Oral administration of L-methylfolate 15 mg per day for 8 weeks.
|
Oral administration of L-methylfolate 15 mg per day for 8 weeks.
The study drug will be given in addition to the standard of care (SOC) for GAD.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-emergent adverse events
Time Frame: Throughout the study, 8 weeks
|
Monitor participants for treatment-emergent adverse events and serious adverse events.
|
Throughout the study, 8 weeks
|
Incidence of treatment-emergent side effects measured with the ASEC
Time Frame: Baseline visit, 4-week visit and 8-week visit.
|
Monitor participants for minor treatment-emergent side effects measured with the Antidepressant Side-Effect Checklist (ASEC). ASEC is a list of 21 possible side effects from antidepressants. Each item is rated from 0 (absent) to 3 (severe). |
Baseline visit, 4-week visit and 8-week visit.
|
Response to treatment defined by CGI-I score below 3
Time Frame: 4-week visit and 8-week visit.
|
Response to treatment, which will be defined as a score of 1 or 2 on the Clinical Global Impression - Improvement (CGI-I) scale. CGI-I is a clinician administered one-item clinical scale rated from 1 (very much improved) to 7 (very much worse). Not assessed would confer score 0. |
4-week visit and 8-week visit.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Remission defined by CGI-S score below 3
Time Frame: 4-week visit and 8-week visit.
|
Remission will be defined as a score of 1 or 2 on the Clinical Global Impression - Severity (CGI-S) scale. CGI-S is a clinician administered one-item clinical scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Not assessed would confer score 0. |
4-week visit and 8-week visit.
|
Change in anxiety severity measured by CGI-S
Time Frame: Baseline visit, 4-week visit and 8-week visit.
|
Changes in scores for CGI-S by comparing the scores in each visit.
CGI-S is a clinician administered one-item clinical scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
Not assessed would confer score 0.
|
Baseline visit, 4-week visit and 8-week visit.
|
Concentration of CRP in serum
Time Frame: Baseline visit and 8-week visit.
|
Collection of blood sample and measurement of the concentration of C-Reactive Protein (CRP) in serum.
|
Baseline visit and 8-week visit.
|
Concentration of homocysteine in serum
Time Frame: Baseline visit and 8-week visit.
|
Collection of blood sample and measurement of the concentration of homocysteine in serum.
|
Baseline visit and 8-week visit.
|
Concentration of vitamin B12 in serum
Time Frame: Baseline visit and 8-week visit.
|
Collection of blood sample and measurement of the concentration of vitamin B12 in serum.
|
Baseline visit and 8-week visit.
|
Concentration of folate in serum
Time Frame: Baseline visit and 8-week visit.
|
Collection of blood sample and measurement of the concentration of folate in serum.
|
Baseline visit and 8-week visit.
|
Change of anxiety symptoms measured with GAD-7
Time Frame: Baseline visit, 4-week visit and 8-week visit.
|
Changes in scores for Generalized Anxiety Disorder 7-item scale (GAD-7) by comparing the scores in each visit. GAD-7 is a self-rated 7-item scale, each item is rated from 0 (not at all) to 3 (nearly every day). |
Baseline visit, 4-week visit and 8-week visit.
|
Change of anxiety symptoms measured with PSWQ
Time Frame: Baseline visit, 4-week visit and 8-week visit.
|
Changes in scores for Penn State Worry Questionnaire (PSWQ) by comparing the scores in each visit. PSWQ is a self-rated 16-item scale, each item is rated from 1 (not at all typical of me) to 5 (very typical of me). |
Baseline visit, 4-week visit and 8-week visit.
|
Change of anxiety symptoms measured with BAI
Time Frame: Baseline visit, 4-week visit and 8-week visit.
|
Changes in scores for Beck Anxiety Inventory (BAI) by comparing the scores in each visit. BAI is a self-rated 21-item scale, each item is rated from 0 (not at all) to 3 (severely - it bothered me a lot). |
Baseline visit, 4-week visit and 8-week visit.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Miller AL. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Altern Med Rev. 2008 Sep;13(3):216-26.
- Saraswathy KN, Ansari SN, Kaur G, Joshi PC, Chandel S. Association of vitamin B12 mediated hyperhomocysteinemia with depression and anxiety disorder: A cross-sectional study among Bhil indigenous population of India. Clin Nutr ESPEN. 2019 Apr;30:199-203. doi: 10.1016/j.clnesp.2019.01.009. Epub 2019 Feb 12.
- Taylor MJ, Carney SM, Goodwin GM, Geddes JR. Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. J Psychopharmacol. 2004 Jun;18(2):251-6. doi: 10.1177/0269881104042630.
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 6038351
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Generalized Anxiety Disorder
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
-
Xijing HospitalRecruitingGeneralized Anxiety DisorderChina
-
Sichuan Jishengtang Pharmaceutical Co., Ltd.Not yet recruitingGeneralized Anxiety Disorder
-
Hospital de Clinicas de Porto AlegreRecruitingGeneralized Anxiety DisorderBrazil
-
University of California, Los AngelesMedical University of South Carolina; Massachusetts General HospitalRecruitingGeneralized Anxiety DisorderUnited States
-
Shahid Beheshti University of Medical SciencesCompletedGeneralized Anxiety DisorderIran, Islamic Republic of
-
Dr. Nazanin AlaviOnline PsychoTherapy ClinicCompletedGeneralized Anxiety DisorderCanada
-
Laureate Institute for Brain Research, Inc.National Institute of Mental Health (NIMH)CompletedGeneralized Anxiety DisorderUnited States
-
The Canadian College of Naturopathic MedicineMassachusetts General Hospital; McGill University; Mitacs; Ekhagastiftelsen; Netherlands... and other collaboratorsActive, not recruitingGeneralized Anxiety DisorderCanada
Clinical Trials on L-methylfolate
-
University of FloridaPamlab, Inc.Completed
-
Pamlab, Inc.Massachusetts General HospitalCompletedSchizophreniaUnited States
-
John D. Dingell VA Medical CenterWithdrawnDepressionUnited States
-
King Edward Medical UniversityRecruiting
-
Carolina Musculoskeletal InstituteBaylor University; Pamlab, L.L.C.CompletedDiabetic Peripheral NeuropathyUnited States
-
Riphah International UniversityCompleted
-
Massachusetts General HospitalPamlab, Inc.CompletedAttention Deficit Hyperactivity DisorderUnited States
-
Northwell HealthTerminatedParkinson's DiseaseUnited States
-
University of ManitobaMicropharma LimitedCompleted
-
Juliano CasonattoUnknown